You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Covishield vaccine being procured by govt at Rs 210 per dose: MoS Health

The Oxford-AstraZeneca vaccine Covishield, manufactured by the Serum Institute of India, is being procured by the government at a lower price of Rs 210 per dose, the Lok Sabha was told on Friday

Topics
Coronavirus Vaccine | Coronavirus

Press Trust of India  |  New Delhi 

Covishield

The Oxford-AstraZeneca COVID-19 vaccine Covishield, manufactured by the Serum Institute of India, is being procured by the government at a lower price of Rs 210 per dose, the Lok Sabha was told on Friday.

Minister of State for Health Ashwini Choubey was responding to a question on whether the government is aware that the Oxford-AstraZeneca vaccine is being sold to European Union nations at comparatively lower price that to India.

As per available information, the price of Oxford-AstraZeneca vaccine across the world is in the range of about USD 4 to USD 5.25. For COVAX AMC facility that pools the demand and supplies for 191 participating countries, including European Union nations, the price is USD 3 per dose to USD 3.15 per dose, which is largely on account of advance payment done to the vaccine manufacturer, much before their vaccine completed clinical trial and obtained licensure from the regulator, he said.

"The Covishield vaccine (Oxford-AstraZeneca vaccine) by the Serum Institute of India is being procured by Govt. of India at a lower price of INR 210 which is around USD 2.7 per dose," Choubey said in a written reply.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Sat, February 13 2021. 07:52 IST
RECOMMENDED FOR YOU